AUTHORS
Davidson Zhao, Noemie Lang2, Yifan Yin, PhD3, Shinya Rai, MD, PhD4, Ting Liu, PhD5, Michael Hong6, Johanna Regala7, Troy Ketela8, Anca Prica9, John Kuruvilla, MD10, Michael Green, PhD11, David Aaron Russler-Germain, MD, PhD12, Pedro Farinha, MD, PhD13, Jan Delabie, MD, PhD14, Ali Sakhdari15, Alexandar Tzankov16, Federico Gaiti, PhD17, Kerry Savage, MD, MSc, BSc18, David Scott, MD19, Tomohiro Aoki, MD, PhD20, Robert Kridel, MD21
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto Medical Biophysics, Toronto, Ontario, Canada
2 Hôpitaux Universitaires de Genève, Genève, Switzerland
3 BC Cancer, Vancouver, Canada
4 BC Cancer, Vancouver, Canada, Kindai University, Osaka-Sayama, Japan
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 University of Texas MD Anderson Cancer Center, Houston, United States
12 Washington University School of Medicine, St. Louis, United States
13 BC Cancer, Vancouver, Canada
14 University Health Network, Toronto, Canada
15 University Health Network, Toronto, Canada
16 University Hospital Basel, Basel, Switzerland
17 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto Medical Biophysics, Toronto, Ontario, Canada
18 BC Cancer, Vancouver, Canada
19 BC Cancer, Vancouver, Canada
20 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
21 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto Medical Biophysics, Toronto, Ontario, Canada
ABSTRACT
Introduction
Post-transplant lymphoproliferative disorders (PTLD) are lymphoid malignancies that develop after solid organ or allogenic stem cell transplantation, and which lead to substantial mortality in transplant patients. The development of PTLD is related to chronic immunosuppression that impairs T cell surveillance. However, the mechanisms involved in the development of PTLD remain incompletely understood. To address this gap, we sought to characterize the biological diversity of tumor B cells and tumor microenvironment (TME) at single cell resolution.
Methods
We performed single-nuclei RNA and Assay for Transposase-Accessible Chromatin sequencing on samples from PTLD patients, including monomorphic PTLD (PTLD-DLBCL n=15, PTLD-BL n=1, of which EBV+ n=4), non-destructive PTLD (n=2, of which EBV+ n=1) and polymorphic PTLD (n=1, EBV+). As controls we included tumor samples from DLBCL patients (n=49) and reactive lymph nodes (RLN, n=3). EBV status was assessed using EBER-ISH and confirmed by the presence of EBV transcripts in single-nuclei data.
Results
After quality control, a total of 285,385 nuclei were included for analysis. Unsupervised clustering revealed 22 cell populations across B, T, myeloid and stromal lineages. Non-destructive PTLD had similar cell type proportions as RLN (median proportions: R=0.96, P<0.001). Unexpectedly, PTLD-DLBCL had similar TME composition as DLBCL (R=0.98, P<0.001), both of which were distinct from non-destructive PTLD and RLN with enrichment of macrophages, exhausted CD8+ T cells and fibroblasts and depletion of plasmacytoid dendritic cells and naïve/memory CD4+ T cells. Within the myeloid compartment, a distinct macrophage subset with robust expression of IFN-responsive genes (e.g. ISG15, IFI6) was expanded in EBV+ PTLD compared to EBV− PTLD (P=0.037), suggesting IFN-mediated polarization of macrophages in EBV+ PTLD.
To further investigate the impact of EBV on the TME of PTLD, we explored cell-cell interactions using CellChat. EBV positivity in PTLD was associated with a distinct inflammatory TME characterized by increased IFN-γ signaling (number of interactions, P=0.013), primarily between exhausted CD8+ T cells and macrophages. Macrophages from EBV+ PTLD samples had a relative upregulation of IFN-responsive genes and other genes with established roles in suppressing T cell function such as IDO1, IL1R2 and VSIG4, suggestive of an immunosuppressive role in EBV+ PTLD pathogenesis. In line with this proposed crosstalk, macrophage-leukocyte adhesion interaction Siglec1-CD43 was increased in EBV+ PTLD (P=0.006) and was predicted to occur between monocytes/macrophages and both CD8+ and CD4+ T cell subsets. Other monocyte/macrophage-T cell interactions differentially enriched according to EBV status included the galectin family (e.g. checkpoint interaction Gal9-TIM3) enriched in EBV+ PTLD (P=0.087), and the PECAM1-CD38 adhesion interaction enriched in EBV− PTLD (P=0.007). Moreover, frequent Siglec1-CD43 interactions were predicted between macrophages and tumor B cells in EBV+ PTLD, suggesting a role of this interaction in directly establishing pro-tumor immunosuppressive niches.
Differential gene expression and chromatin accessibility analysis of tumor B cells from monomorphic PTLD revealed upregulation of genes associated with EBV infection in EBV+ PTLD, including CD274 (PD-L1), SAMSN1, VIM and SUB1. In contrast, neoplastic B cells from EBV− PTLD had a relative upregulation of anti-apoptotic transcription factors including BCL11A, FOXP1 and BCL6. Across all PTLD subtypes, tumor B cells demonstrated coordinated reductions in MHC-II chromatin accessibility and gene expression relative to non-neoplastic B cells, accompanied by reduced CIITA expression. Although MHC-II loss has been described in subsets of DLBCL, this phenotype was consistently observed across PTLD categories irrespective of EBV status. In contrast, reduced MHC-I expression and accessibility were observed in DLBCL and EBV− PTLD, whereas EBV+ PTLD retained MHC-I expression despite malignant transformation.
Conclusions
Single nuclei profiling identifies two mechanisms of immune evasion in PTLD: an EBV-associated immunosuppressive macrophage-T cell crosstalk and widespread suppression of the CIITA/MHC-II antigen presentation axis. Our findings offer novel insights into PTLD pathobiology and warrant further investigation of targeting these axes for immune-based therapeutic strategies.
DISCLOSURES
Davidson Zhao: No relevant conflicts of interest to declare.